Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
American Journal of Clinical Dermatology
Erschienen in: American Journal of Clinical Dermatology 11/2003

01.11.2003 | Therapy in Practice

Optimal Management of Hair Loss (Alopecia) in Children

verfasst von: Shannon Harrison, Dr Rodney Sinclair

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 11/2003

Einloggen, um Zugang zu erhalten

Abstract

Hair loss in children encompasses a wide range of conditions that can be congenital or acquired. A congenital hair abnormality may be an isolated finding in an otherwise healthy child or may exist as a feature of a clinical syndrome. A thorough understanding of basic hair biology and normal hair development enables accurate assessment of the child with hair loss. Knowledge of the normal range and variation observed in children’s hair additionally enhances this assessment. Social and cultural factors also influence these norms.
The psychological and cosmetic importance of hair is immense in our society. The clinical presentation of pediatric hair disorders ranges from subtle to disfiguring. Management of hair disorders requires a holistic approach to the child and family. Young children usually lack self-awareness and it may be the parent who, projecting their own concerns onto the child, most acutely feels any associated anxiety. In addition, parents of a child with an inherited hair condition often feel guilt, and siblings can develop unsupported fears that they may be affected. Hair loss for the older child can lead to low self-esteem, depression and humiliation.
Congenital and hereditary hypotrichosis and hair shaft abnormalities often have no effective treatment. There is a variety of treatment options for alopecia areata and telogen effluvium, but no single treatment is 100% effective. Tinea capitis is an infective condition of the hair that responds readily to the appropriate medical therapy. If no effective treatment for the hair loss exists, cosmetic camouflage with wigs is the best option.
Fußnoten
1
Use of tradenames is for product identification only and does not imply endorsement.
 
Literatur
1.
Lavker RM, Bertolino AP, Klein LM, et al. Biology of hair follicles. In:Fitzpatick TB, Eisen AZ, Wollf K, et al., editors. Dermatology in general medicine. 5th ed., Boston: McGraw-Hill, 1993: 230–8
2.
Sinclair RD, Banfield CC, Dawber RP. Hair structure and function. In: Sinclair RD, Banfield CC, Dawber RP, editors. Handbook of diseases of the hair and scalp. Oxford: Blackwell Science, 1999: 3–23
3.
4.
Wade M, Sinclair RD. Disorders of hair. In: Parish LC, Brenner S, Ramos-e-Silva M, editors. Women’s dermatology from infancy to maturity. Carnforth: Parthenon Publishing, 2001: 126–59
5.
Dawber RP, de Berker D, Wojnarowska F. Disorders of the hair. In: Champion RH, Burton JL, Burns DA, Breathnach SM, editors. Rook/Wilkinson/Ebling textbook of dermatology. 6th ed. Oxford: Blackwell Science, 1998: 2885–973
6.
Reynolds EL. The appearance of adult patterns of body hair in man. Ann N Y Acad Sci 1951; 53: 576–84PubMedCrossRef
7.
Gilhar A, Shalaginov R, Assy B, et al. Alopecia areata is a T-lymphocyte mediated autoimmune disease: lesional human T-lymphocytes transfer alopecia areata to human skin grafts on SCID mice. J Investig Dermatol Symp Proc 1999 Dec; 4 (3): 207–10PubMedCrossRef
8.
Safavi K. Prevalence of alopecia areata in the first national health and nutrition examination survey. Arch Dermatol 1992; 128: 702–4PubMedCrossRef
9.
Messenger R, Simpson N. Alopecia areata. In: Dawber R, editor. Diseases of the hair and scalp. Oxford: Blackwell Science, 1997: 338–69
10.
Gip L, Lodin A, Molin L. Alopecia areata: a follow-up investigation of outpatient material. Acta Derm Venereol (Stockh) 1969; 49: 180–8
11.
Green J, Sinclair RD. Genetics of alopecia areata. Australas J Dermatol 2000 Nov; 41 (4): 213–8PubMedCrossRef
12.
Muller SA, Winkelmann RK. Alopecia areata. Arch Dermatol 1963; 88: 106–13
13.
14.
Duvic M, Nelson A, de Andrade M. The genetics of alopecia areata. Clin Dermatol 2001; 19 (2): 135–9PubMedCrossRef
15.
du Vivier A, Munro DD. Alopecia areata, autoimmunity and Down’s syndrome. BMJ 1975; 1: 191–2PubMedCrossRef
16.
Carter DM, Jegasothy BV. Alopecia areata and Down’s syndrome. Arch Dermatol 1976; 112: 1397–9PubMedCrossRef
17.
Sinclair RD, Banfield CC, Dawber RP. Alopecia areata. In: Sinclair RD, Banfield CC, Dawber RP, editors. Handbook of diseases of the hair and scalp. Oxford: Blackwell Science, 1999: 139–40
18.
Eckert J, Church RE, Ebling FJ. The pathogenesis of alopecia areata. Br J Dermatol 1968; 80: 203–10PubMedCrossRef
19.
Muralidhar S, Sharma VK, Kaur S. Ophiasis inversus: a rare pattern of alopecia areata [letter]. Pediatr Dermatol 1998; 15: 326–7PubMedCrossRef
20.
Madini S, Shapiro J. Alopecia areata update. J Am Acad Dermatol 2000; 42: 549–66
21.
Mitchell A, Krull E. Alopecia areata: pathogenesis and treatment. J Am Acad Dermatol 1984; 11: 763–75PubMedCrossRef
22.
So A. Genetics, polymorphism and regulation of expression of HLA region genes. In:Lecher R, editor. HLA and disease. San Diego (CA): Academic Press, 1994: 1
23.
Price VH, Colombe BW. Heritable factors distinguish two types of alopecia areata. Dermatol Clin 1996; 14: 679–89PubMed
24.
Colombe BW, Price VH, Khoury EL. HLA class II antigen association help to define two types of alopecia areata. J Am Acad Dermatol 1995; 33: 757–64PubMed
25.
Frentz G, Thomsen K, Jakobsen BK, et al. HLA-DR4 in alopecia areata [letter]. J Am Acad Dermatol 1986; 14: 129–30PubMedCrossRef
26.
Orrechia G, Belvedere MC, Martinetti M. Human leukocyte antigen region involvement in the genetic predisposition to alopecia areata. Dermatologica 1987; 175: 10–4CrossRef
27.
Duvic M, Hordinsky MK, Fiedler VC. HLA-D locus associations in alopecia areata Drw52a may confer disease resistance. Arch Dermatol 1991; 127: 64–8PubMedCrossRef
28.
Welsh EA, Clark HH, Zane S, et al. Human leukocyte antigen DQB01*03 alleles are significantly associated with alopecia areata. J Invest Dermatol 1994; 103: 758–63PubMedCrossRef
29.
Duvic M, Welsh EA, Jackow C, et al. Analysis of HLA-D locus alleles in alopecia areata patients and their families. Arch Dermatol 1995; 104 (5 Suppl.): 5S-6S
30.
Tarlow JK, Clay FE, Cork MJ. Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene. J Invest Dermatol 1994; 103: 387–90PubMedCrossRef
31.
Fiedler VC. Alopecia areata: a review of therapy, efficacy, safety and mechanism. Arch Dermatol 1992; 128: 1519–29PubMedCrossRef
32.
Gill KA, Baxter DL. Alopecia totalis: treatment with fluocinolone acetonide. Arch Dermatol 1963; 87: 384–6PubMedCrossRef
33.
Leyden JJ, Kligman AM. Treatment of alopecia areata with steroid solution [letter]. Arch Dermatol 1972; 106: 924PubMedCrossRef
34.
Pascher F, Kurtin S, Andrade E. Assay of 0.2% fluocinolone acetonide cream for alopecia areata and totalis. Dermatologica 1970; 141: 193–202PubMedCrossRef
35.
Abell E, Munro DD. Intralesional treatment of alopecia areata with triamcinolone acetonide by jet injector. Br J Dermatol 1979; 88: 55–9CrossRef
36.
Schmoekel C, Weissman I, Plewig G, et al. Treatment of alopecia areata by anthralin-induced dermatitis. Arch Dermatol 1979; 115: 1254–5CrossRef
37.
Fiedler-Weiss VC, Buys CM. Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatol 1987; 123: 1491–3PubMedCrossRef
38.
Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol 1987; 16: 730–6PubMedCrossRef
39.
Price VH. Topical minoxidil (3%) in extensive alopecia areata including long term efficacy. J Am Acad Dermatol 1987; 16: 737–44PubMedCrossRef
40.
Kratha J, Goerz G, Vizethum W. Dinitrochlorobenzene: influence on the cytochrome P450 system and mutagenic effects. Arch Dermatol Res 1979; 266: 315–8CrossRef
41.
Wiseman MC, Shapiro J, MacDonald N, et al. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol 2001; 137: 1063–8PubMed
42.
Schuttelaar M-LA, Hamstra JJ, Plink EPB, et al. Alopecia areata in children: treatment with diphencyprone. Br J Dermatol 1996; 135: 581–5PubMedCrossRef
43.
MacDonald Hull SP, Pepall L, Cunliffe WJ. Alopecia areata in children: response to treatment with diphencyprone. Br J Dermatol 1991; 125: 164–8CrossRef
44.
Orecchia G, Malagoli P. Topical immunotherapy in children with alopecia areata. J Invest Dermatol Suppl 1995; 104: 35S-6S
45.
Tosti A, Guidetti MS, Bardazzi F, et al. Long-term results of topical immunotherapy in children with alopecia totalis or alopecia universalis. J Am Acad Dermatol 1996; 35: 199–201PubMedCrossRef
46.
Pardasani AG, Turner E, McMichael AJ. Squaric acid dibutylester: indications for use and efficacy in alopecia areata. Arch Dermatol 2001; 137: 970–2PubMed
47.
Kligman A. Pathological dynamics of reversible hair loss in humans: I. telogen effluvium: Arch Dermatol 1961; 83: 175–98PubMedCrossRef
48.
49.
Wise RP, Kiminyo KP, Salive ME. Hair loss after routine immunization. JAMA 1997; 278: 1176–8PubMedCrossRef
50.
51.
Sinclair R. There is no clear association between low serum ferritin and chronic diffuse telogen hair loss. Br J Dermatol 2002; 147: 982–4PubMedCrossRef
52.
53.
Feidler VV, Hafeez A. Diffuse alopecia: telogen hair loss. In: Olsen EA, editor. Disorders of hair growth; diagnosis and treatment (New York (NY)): McGraw-Hill, 1994: 249–52
54.
55.
56.
Weismann K. Zinc metabolism and the skin. In: Rook ASJ, Savin JA, editors. Recent advances in dermatology 5. Edinburgh: Churchill Livingston, 1980: 109–29
57.
58.
Elston D, Bergfield W. Cicatricial alopecia (and other causes of permanent hair loss). In:Olsen EA, editor. Disorders of hair growth; diagnosis and treatment. New York (NY): McGraw Hill, 1994: 287
59.
Bradfield R, Bailley M. Hair root response to protein undernutrition. In: Montagna W, Dobson R, editors. Advances in biology of the skin: vol. IX, hair growth. Oxford: Pergamon, 1968: 109
60.
Skolnik P, Eaglstein W, Ziboh V. Human essential fatty acid deficiency. Arch Dermatol 1977; 113: 939–41PubMedCrossRef
61.
62.
Van Dijke CP, Heydendael RJ, de Kleine MJ. Methimazole, carbimazole and congenital skin defects. Ann Intern Med 1987; 106: 60–1PubMed
63.
Sinclair RD, Banfield CC, Dawber RP. Hereditary and congenital alopecias and hypotrichosis. In: Sinclair RD, Banfield CC, Dawber RP, editors. Handbook of diseases of the hair and scalp. Oxford: Blackwell Science, 1999: 129–55
64.
Trakimas CA, Sperling LC. Temporal triangular alopecia acquired in adulthood. J Am Acad Dermatol 1999; 40: 842–4PubMedCrossRef
65.
Sprecher E, Bergman R, Szargel R. Atrichic with papular lesions maps to 8p in the region containing the human hairless gene. Am J Hum Genet 1998; 80 (5): 546–50
66.
Roberts JL, Whiting DA, Henry D, et al. Marie Unna congenital hypotrichosis: clinical description, histopathology, scanning electron microscopy of a previously unreported large pedigree. J Invest Dermatol Symp Proc 1999 Dec; 4 (3): 261–7CrossRef
67.
Roberts JL, Wong CQ, Stenn KS. Marie Unna hereditary hypotrichosis gene maps to human chromosome 8p21 near hairless. J Invest Dermatol 2000; 114: 595–7PubMedCrossRef
68.
Van Steensel M, Smith FJ, Steijlen PM, et al. The gene for hypotrichosis of Marie Unna maps between D8S258 and D8S298: exclusion of the hr gene by cDNA and genomic sequencing. Am J Hum Genet 1999; 65: 413–9PubMedCrossRef
69.
70.
de Berker D, Sinclair RD. The hair shaft: normality, abnormality, and genetics. Clin Dermatol 2001 Mar/Apr; 19 (2): 129–34PubMedCrossRef
71.
Sinclair RD, Banfield CC, Dawber RPR. Structural abnormalities of the hair shaft. In: Sinclair RD, Banfield CC, Dawber RP, editors. Handbook of diseases of the hair and scalp. Oxford: Blackwell Science, 1999: 156–87
72.
McGowan KM, Coulombe PA. Keratin 17 expression in the hard epithelial context of the hair and nail, and its relevance for the pachyonychia congenita phenotype. J Invest Dermatol 2000; 114: 1101–7PubMedCrossRef
73.
Bjornstad RT. Pili torti and sensory-neural loss of hearing. Paper presented at the 17th Combined Dermatological Association Meeting, Copenhagen, Denmark: May 27–29 1965, Copenhagen
74.
Lubianca Neto JF, Lu L, Eavey RD, et al. The Bjornstad syndrome (sensorineural hearing loss and pili torti) gene maps to chromosome 2q34–36. Am J Hum Genet 1998; 62: 1107–12PubMedCrossRef
75.
Tumer Z, Tommerup N, Tonnesen T, et al. Mapping of the Menke’s locus to Xq13.3 distal to the X-activation center by an intrachromosomal insertion of the segment Xq13.3-q21.2. Hum Genet 1992; 88: 668–72PubMedCrossRef
76.
Vulpe C, Levison B, Whitney S, et al. Isolation of a candidate gene for Menke’s disease and evidence that it encodes a copper-transporting ATPase. Nat Genet 1993; 3: 7–13PubMedCrossRef
77.
Jones LN. Investigation of structural proteins in human hair defects using anagen follicles. Br J Dermatol 1996; 135: 80–5PubMedCrossRef
78.
Healy E, Holmes SC, Belgaid CE, et al. A gene for monilethrix is closely linked to the type II keratin gene cluster at 12q13. Hum Mol Genet 1995; 4 (12): 2399–402PubMedCrossRef
79.
Winter H, Rogers MA, Langbein L, et al. Mutations in the hair cortex keratin hHhB6 cause the inherited hair disease monilethrix. Nat Genet 1997; 16: 372–4PubMedCrossRef
80.
Winter H, Rogers MA, Gebhardt M, et al. A new mutation in the type II hair cortex keratin hHb1 involved in the inherited hair disorder monilethrix. Hum Genet 1997; 101: 165–9PubMedCrossRef
81.
Chavanas S, Garner C, Bodemer C, et al. Localisation of the Netherton syndrome gene to chromosome 5q32, by linkage analysis and homozygosity mapping. Am J Am Genet 2000; 66: 914–21CrossRef
82.
Chavanas S, Bodemer C, Rochat A, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 2000; 25: 141–2PubMedCrossRef
83.
Hamm H, Traupe H. Loose anagen hair of childhood: the phenomenon of easily pluckable hair. J Am Acad Dermatol 1989; 20: 242–8PubMedCrossRef
84.
Sinclair RD, Cargnello J, Chow CW. Loose anagen syndrome. Exp Dermatol 1999; 8 (4): 297–8PubMed
85.
Sinclair RD, Banfield CC, Dawber RPR. Non-scarring traumatic alopecia. In:Sinclair RD, Banfield CC, Dawber RPR,editors. Handbook of diseases of the hair and scalp. Oxford: Blackwell Science, 1999: 85–91
86.
Whiting DA. Traumatic alopecia. Int J Dermatol 1998; 38 Suppl. 1: 34–44CrossRef
87.
88.
Sinclair RD, Banfield CC, Dawber RPR. Infections and infestations of the hair. In: Sinclair RD, Banfield CC, Dawber RPR, editors. Handbook of diseases of the hair and scalp. Oxford: Blackwell Science, 1999: 191–200
89.
90.
Aly R. Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol 1994; 31 (3 Pt 2): S21–5CrossRef
91.
Hay RJ, Clayton YM, De Silva N, et al. Tinea capitis in south-east London: a new pattern of infection with public health implications. Br J Dermatol 1996; 135: 955–8PubMedCrossRef
92.
Kemna ME, Elewski BE. A US epidemiologic survey of superficial fungal diseases. J Am Acad Dermatol 1996; 35: 539–42PubMedCrossRef
93.
Higgins EM, Fuller LC, Smith CH. Guidelines for the management of tinea capitis. Br J Dermatol 2000; 143: 53–8PubMedCrossRef
94.
Hay RJ, Moore M. Mycology. In: Champion RH, Burton JL, Burns DA, Breathnach SM, editors. Textbook of dermatology. 6th ed. Oxford: Blackwell Science, 1988: 1277–376
95.
Babel DE, Baughman SA. Evaluation of the adult carrier state in juvenile tinea capitis. J Am Acad Dermatol 1989; 21: 1209–12PubMedCrossRef
96.
Carslaw RW. Favus of the scalp: observations on the manner of spread. Br J Dermatol 1955; 67: 392–6PubMedCrossRef
97.
MacKenzie DWR, Burrows D, Walby AL. Trichophyton sulphureum in a residential school. BMJ 1960; 2: 1055–8PubMedCrossRef
98.
Dawber RPR, Fenton DA. Infections and infestations. In: Dawber RPR, editor. Diseases of the hair and scalp. 3rd ed. Oxford: Blackwell Science, 1997: 418–60
99.
Wade MS, Sinclair RD. Disorders of hair in infants and children other than alopecia. Clin Dermatol 2002; 20: 16–28PubMedCrossRef
100.
Elewski BE. Treatment of tinea capitis: beyond griseofulvin. J Am Acad Dermatol 1999; 40 (6 Pt 2): S27–30CrossRef
101.
Elewski BE. Treatment of tinea capitis with itraconazole. Int J Dermatol 1997; 36: 537–41CrossRef
102.
Abdel-Rahman SM, Powell DA, Nahata MC. Efficacy of itraconazole in children with Trichophyton tonsurans tinea capitis. J Am Acad Dermatol 1998; 38: 443–6PubMedCrossRef
103.
Lopez-Gomez S, Del Palacio A, Van Custem J, et al. Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind randomized control study in children. Int J Dermatol 1994; 33: 743–7PubMedCrossRef
104.
Mercurio MG, Silverman R, Elewski BE. Tinea capitis: fluconazole in Trichophyton tonsurans infection. Pediatr Dermatol 1998; 15: 229–32PubMedCrossRef
105.
Soloman BA, Collins R, Sharma R, et al. Fluconazole for the treatment of tinea capitis in children. J Am Acad Dermatol 1997; 37: 274–5CrossRef
Metadaten
Titel
Optimal Management of Hair Loss (Alopecia) in Children
verfasst von
Shannon Harrison
Dr Rodney Sinclair
Publikationsdatum
01.11.2003
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 11/2003
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200304110-00004

Weitere Artikel der Ausgabe 11/2003

American Journal of Clinical Dermatology 11/2003 Zur Ausgabe

Review Article

Role of Topical Emollients and Moisturizers in the Treatment of Dry Skin Barrier Disorders

Commentary

The Dermatologist’s Academic Portfolio

Review Article

Fragrance Contact Allergy

Case Reports

Cutaneous Psammomatous Melanotic Schwannoma

Pharmacovigilance

Cutaneous Drug Reaction Case Reports

Therapy in Practice

Potential Role of Estrogens in Wound Healing

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise